harm-Olam International, the US-based contract research organisation (CRO) that recently announced it was on the lookout for acquisitions, has formed a strategic alliance with Canadian CRO JSS Medical Research.
According to Pharm-Olam, the alliance will give it access to JSS Medical’s expertise in post-marketing observational, health economics and outcomes studies, which the Canadian CRO conducts for global pharmaceutical, biotechnology, medical device, nutraceutical and consumer health companies.
Founded in 1997 by McGill University professor Dr John S Sampalis, JSS Medical Research is a Phase I to Phase IV clinical research organisation specialising in outcomes research. For its part, the company will benefit from Pharm-Olam’s global coverage in more than 40 countries spanning the US, Europe, Russia, Latin America, India and South Africa, the partners noted.
“This is another milestone in the deployment of JSS Medical Research’s international growth strategy, after opening our offices in Ontario and New Jersey in 2008,” Sampalis commented.
Matt Delaney, director of strategic development for Pharm-Olam, said the alliance put the CRO in an “even better” position to meet the growing demand for specialised services such as health outcomes research, while expanding its presence in Canada.